Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation

Figure 1 Study design.

Figure 2 CONSORT flow diagram.

Figure 3 Abdominal pain. A: Abdominal pain score evolution; B: Area under the curve (W5-W8) of abdominal pain; C: Percentage of abdominal pain responders in the ITT population. Significant result (^aP < 0.05, Chi² test). Similar profiles were obtained for the PP population (Supplementary Figure 1).

Figure 4 Irritable bowel syndrome-specific quality of life questionnaire scores at the end of the intervention (V3) in the PP population. Significant result (^aP < 0.05, ANOVA model).

Figure 5 Irritable bowel syndrome-specific quality of life questionnaire scores at the end of the intervention (V3) adjusted to baseline (V1) in ITT abdominal pain responders supplemented with Saccharomycescerevisiae CNCM I-3856. PP population radar plot: Supplementary Figure 3. Significant result (^aP < 0.05, ANCOVA for repeated measures). Between-group differences are shown in Supplementary Table 2.